作为小说冠状病毒继续在美国和国外传播，新的希望可能出现在研发疫苗的竞赛中。
辉瑞作为少数几家竞相开发疫苗的公司之一，该公司周三公布了其早期试验的有希望的新数据。
辉瑞公司的疫苗开发人员菲尔·多米特泽(Phil Dormitzer)向美国广播公司新闻部讲述了该公司疫苗的新数据，他称之为“非常令人兴奋”，并分享了更多关于潜在发布时间表和疫苗功效的信息。
他在接受《今夜世界新闻》采访时说:“我们今天展示的是美国第一批候选疫苗试验的初步中期数据。”“我们的第一个候选疫苗是激发抗体水平来中和病毒，这相当于或优于你在患有COVID-19的人群中看到的情况。”
“这是一项巨大的工作，现在看到结果开始出现，我们感到非常自豪，”他补充道。“有可能真正改变很多人的生活。”
“在这个项目中，我们进展很快。但这并不意味着我们在偷工减料或降低安全标准，”他解释道，并补充道，辉瑞正在采取必要措施确保候选疫苗的安全性。
Philip Dormitzer，疫苗研究者/开发者。
“如果这是成功的，并以我们希望的规模推广，我们可以防止大量的伤害发生，”他说，这种病毒可能的疫苗已经杀死了全球512，000多人。“这与辉瑞和疫苗部门的总体任务非常一致，在这两个部门，这不是我们已经或正在开发的唯一主要病原体疫苗。但是很难想象还有另一种病原体像这种病毒一样对社会造成如此大的破坏，导致了今天如此多的恐惧。"
虽然制造商还没有给出具体的发布日期，但多米特兹向美国广播公司保证，辉瑞公司“目前正在实现到年底生产1亿剂以及到2021年再生产12亿剂的目标”。
他说:“我们设定的目标是在2020年分发数百万剂疫苗，并在此基础上执行，这当然意味着一切都要顺利。”。“我们需要监管机构的批准才能这样做。但这是我们的计划。”
随着试验的继续，多米特泽说他们也在“密切跟踪病毒的进化”，以减少任何可能降低疫苗影响的突变。
“你确实在病毒中看到了一些突变，但幸运的是，我们没有看到任何会降低疫苗效力的突变迹象，”他说。
随着该公司继续研究可能的疫苗，Dormitzer说“毫无疑问”，如果疫苗投放市场，需求将超过最初的产量。
他说:“当一种有效的疫苗首次出现时，需求将超过供给，因此，在这一点上，我们正在做很多工作来提高我们的生产能力。”。
2020年5月4日，在巴尔的摩的马里兰大学医学院，第一名患者参加了辉瑞公司的COVID-19冠状病毒疫苗临床试验，并接受了注射。2020年7月1日，星期三，辉瑞公司和它的德国合作伙伴BioNTech对四种实验性COVID-19疫苗进行了测试，其中第一种疫苗在45人的早期测试中显示出令人鼓舞的结果。
本月晚些时候，与德国合作伙伴生物技术公司一起开发疫苗的制药公司将在下一阶段的试验中测试3万多名志愿者。
世界卫生组织最近宣布，17种潜在疫苗正在进行人体试验，其中132种处于临床前阶段。
据世界卫生组织称，支持牛津大学疫苗试验的阿斯利康、中国的坎西诺和美国的莫德纳是实验室结果有希望的领先者。
据报道，牛津的疫苗目前处于试验的第三阶段，已经招募了10，000多名志愿者。早期结果发现，该试验在紧急剂量下是安全有效的，并可能在10月份准备开发。
中国军方已经被允许使用其研究团队和加拿大生物制品公司开发的疫苗。
美国生物技术公司Moderna将于本月晚些时候开始第三阶段的人体试验，共有30，000名志愿者。如果试验成功，莫德娜说，它希望在2021年初准备好剂量。
支持莫德纳疫苗的美国国家卫生研究院称，该公司的成功率估计为80%至90%。
2020年6月28日，在休斯顿的墨西哥领事馆，一名男子在由美国纪念医学中心提供的免费COVID-19测试点接受测试。
尽管试验的进展看起来很有希望，但一些专家警告说，疫苗开发本身的成功并不是唯一的障碍。
“开发安全有效的疫苗并不是唯一的挑战。我们需要足够的供应和潜在的数亿美国人接种疫苗，以实现群体免疫，”美国广播公司新闻医学撰稿人、南岸健康部传染病主任托德·埃勒林博士说。
一些医生认为，关键是公司要在试验阶段测试大量的老年人和年轻人，以证明任何疫苗的有效性和安全性。
“如果我们在这些事情上走捷径，我不认为我们会创造人们需要的信心，”哈佛全球健康研究所主任阿什什·贾博士告诉美国广播公司新闻。我们必须做好。"
Early trial results keep Pfizer vaccine development on track for possible 2020 distribution
As the novelcoronaviruscontinues to spread across the U.S. and abroad, new hope may be emerging in the race to develop a vaccine.
Pfizer, one of a handful of companies racing to develop a vaccine, reported promising new data Wednesday from its early stages of trials.
Phil Dormitzer, a vaccine developer at Pfizer, spoke to ABC News about the new data from the company's vaccine, which he called "tremendously exciting," and shared more about a potential release timeline and the vaccine's efficacy.
"What we're presenting today is preliminary interim data from the United States trial for the first of those vaccine candidates," he said in an interview with "World News Tonight." "Our first vaccine candidate is eliciting antibody levels to neutralize the virus that is equivalent to or better than what you see in people who have had COVID-19."
"It's been a tremendous amount of work and there's now a lot of pride to see the results start to come forward," he added. "The potential is there to actually change a lot of people's lives."
"In this program, we're going fast. But that does not mean that we're cutting corners or having any lowering of the safety standards," he explained, adding that Pfizer is doing what is necessary to make sure the vaccine candidates are safe.
Philip Dormitzer, vaccine researcher/developer.
"If this is successful and is rolled out in the scale that we hope it is, we could prevent a tremendous amount of harm from occurring," he said about the possible vaccine for the virus that has killed over 512,000 people worldwide. "This is very much in line with the overall mission of Pfizer and the vaccine's division, where this is not the only major pathogen against which we either have or are developingvaccines. But it's hard to imagine another pathogen that has been as disruptive to society that is causing as much fear today as this virus is."
While the manufacturer has not given a specific release date, Dormitzer assured ABC News Pfizer is "currently on track" to meet the goal of producing 100 million doses by the end of the year and another 1.2 billion doses in 2021.
"The goal that we've set is to distribute millions of vaccine doses in 2020 and executing on that, of course, means everything has to go well," he said. "We need the regulatory approval to do so. But that is our plan."
As the trials continue, Dormitzer said they are also "tracking the evolution of the virus closely" to mitigate any possibilities of mutation that could potentially decrease the impact of the vaccine.
"You do see some mutation in the virus, but fortunately we've not seen any indication of mutations that would decrease the efficacy of the vaccine," he said.
As the company continues its work on the possible vaccine, Dormitzer said "there's no question" that demand will outmatch initial production if the vaccine hits the market.
"When an effective vaccine is first available, there will be more demand than there is supply, so we're doing a lot to, at this point, ramp up our ability to produce," he said.
The first patient enrolled in Pfizer's COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, receives an injection, May 4, 2020. The first of four experimental COVID-19 vaccines being tested by Pfizer and its German partner BioNTech showed encouraging results in very early testing of 45 people, the companies said Wednesday, July 1, 2020.
Later this month, the pharmaceutical company, which is developing the vaccine alongside German partner BioNTech, will test 30,000 more volunteers in the next phase of trials.
The World Health Organization recently announced that 17 potential vaccines are in human trials with 132 in preclinical phases.
According to the WHO, AstraZeneca, which is supporting Oxford University's vaccine trials, CanSino in China, and U.S.-based Moderna are among the front-runners with promising lab results.
Oxford's vaccine is reportedly the farthest along as it is currently in phase 3 of trials and has enlisted over 10,000 volunteers. The early results found the trial to be safe and effective in emergency doses and could be ready for development by October.
The Chinese military has been greenlighted to use a vaccine developed by its research teams and CanSino Biologics.
The American biotech company Moderna is set to begin its third phase of human trials later this month with 30,000 volunteers. If the trials are a success, Moderna said it hopes to have doses ready by early 2021.
The National Institutes of Health, which backs Moderna's vaccine, said it estimates the company's success at 80% to 90%.
A man is tested at a free COVID-19 testing site, provided by United Memorial Medical Center, June 28, 2020, at the Mexican Consulate, in Houston.
And while the progress in development at the trials looks promising, some experts warn that success in developing the vaccine itself isn't the only hurdle.
"Developing safe and effective vaccines isn't the only challenge. We need to have enough supply and potentially hundreds of millions of Americans to get vaccinated in order to achieve herd immunity," Dr. Todd Ellerin, director of infectious diseases at South Shore Health and an ABC News medical contributor, said.
The key, according to some doctors, is for companies to test large numbers of people both old and young during the trial phase to prove the efficacy and safety of any vaccine.
"If we sort of cut corners on those things, I don't think we'll create the confidence people need," Dr. Ashish Jha, director of the Harvard Global Health Institute, told ABC News. 'We have to do it right."
